RT Journal Article
SR Electronic
T1 The Impact of Timing of EGFR and IGF-1R Inhibition for Sensitizing Head and Neck Cancer to Radiation
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3029
OP 3035
VO 32
IS 8
A1 FUMIHIKO MATSUMOTO
A1 DAVID N. VALDECANAS
A1 KATHRYN A. MASON
A1 LUKA MILAS
A1 K. KIAN ANG
A1 UMA RAJU
YR 2012
UL http://ar.iiarjournals.org/content/32/8/3029.abstract
AB Background: Targeting the epidermal growth factor receptor (EGFR) improved radiotherapy outcome by 10-15% in head and neck tumors (HNSCC). We tested the therapeutic benefits of co-targeting EGFR and insulin-like growth factor-1 receptor (IGF-1R) to further enhance tumor response to radiation. Materials and Methods: Mice bearing FaDu tumor xenografts were treated with ganitumab (previously known as AMG479, an anti-IGF-1R antibody), panitumumab (an anti-EGFR antibody), or both in combination with fractionated doses of radiation. Tumor growth delay and tumor cure/recurrence served as end-points. Results: The best tumor growth delay was achieved when ganitumab and panitumumab were given concurrently with radiation. Tumor cure/recurrence studies showed that combining ganitumab, panitumumab and radiation resulted in significantly higher radiocurability rates than use of either of the agents given with radiation. Conclusion: These findings provide the rationale for clinical testing of the combination of ganitumab and panitumumab for the treatment of HNSCC.